SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 29, 2006
GENEX PHARMACEUTICAL, INC.
| Delaware | 333-102118 | 98-0383571 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
1801 Guangyin Building, Youyibeilu, Hexi District,
Tianjin
City, China 300074
(Address of principal executive offices) (Zip Code)
86-22-233-70440
(Registrant's telephone number, including area code)
KS E-Media Holdings, Inc.
(Former name, former address and former fiscal year, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 4.01 Change in Registrant's Certifying Accountant Effective March 29, 2006, GC Alliance Limited ("GC Alliance")
resigned as the Registrant's principal accountant engaged to audit the
Registrant's financial statements. Previously, GC Alliance had replaced Kabani &
Company, which had reported on the Registrant's financial statements for the
years ended December 31, 2004 and December 31, 2003 and was dismissed by the
Registrant effective November 16, 2005. GC Alliance resigned because it will not
be able to complete the process of demonstrating to the Office of the Chief
Accountant, prior to the date when the Registrant's Annual Report on Form 10-KSB
for its fiscal year ended December 31, 2005 is required to be filed, that it
has the requisite knowledge and experience in applying US GAAP, PCAOB Standards,
SEC financial reporting rules and SEC independence requirements. GC Alliance has
provided the Registrant with a letter, a copy of which is filed as an exhibit
with this Form 8-K, which confirms its agreement with the statements made by the
Registrant in this paragraph. There were no disagreements with GC Alliance and
it had not audited the Registrant's financial statements for any period. Effective March 29, 2006, the Registrant retained the firm of
Schwartz Levitsky Feldman LLP as the auditors of the Registrant for the fiscal
year ended December 31,2005. The Registrant has been advised by Schwartz
Levitsky and Feldman LLP that it is a firm which has demonstrated its knowledge
and experience in applying the above specified standards, rules and requirements
to the Office of the Chief Accountant. Item 9.01 Financial Statements and Exhibits Exhibits 16.1 Letter of GC Alliance Limited dated April 4, 2006, regarding the change
in certifying accountant. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| GENEX PHARMACEUTICAL, INC. | |
| Date: April 4, 2006 | By: |
| /s/ Fuzhi Song | |
| Fuzhi Song | |
| Chief Executive Officer |